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Hereditary gingival fibromatosis (HGF) is a rare, autosomal dominant form of gingival overgrowth. Affected
individuals have a benign, slowly progressive, nonhemorrhagic, fibrous enlargement of the oral masticatory mucosa.
Genetic loci for autosomal dominant forms of HGF have been localized to chromosome 2p21-p22 (HGF1) and
chromosome 5q13-q22 (HGF2). To identify the gene responsible for HGF1, we extended genetic linkage studies
to refine the chromosome 2p21-p22 candidate interval to ∼2.3 Mb. Development of an integrated physical and
genetic map of the interval identified 16 genes. Sequencing of these genes, in affected and unaffected HGF1 family
members, identified a mutation in the Son of sevenless–1 (SOS1) gene in affected individuals. In this report, we
describe the genomic structure of the SOS1 gene and present evidence that insertion of a cytosine between nucleotides
126,142 and 126,143 in codon 1083 of the SOS1 gene is responsible for HGF1. This insertion mutation, which
segregates in a dominant manner over four generations, introduces a frameshift and creates a premature stop codon,
abolishing four functionally important proline-rich SH3 binding domains normally present in the carboxyl-terminal
region of the SOS1 protein. The resultant protein chimera contains the wild-type SOS1 protein for the N-terminal
amino acids 1–1083 fused to a novel 22–amino acid carboxyl terminus. Similar SOS1 deletion constructs are
functional in animal models, and a transgenic mouse construct with a comparable SOS1 chimera produces a
phenotype with skin hypertrophy. Clarification of the functional role of this SOS1 mutant has implications for
understanding other forms of gingival fibromatosis and corrective gingival-tissue management.
Introduction
Hereditary gingival fibromatosis (HGF) is a genetically
heterogeneous overgrowth condition characterized by a
benign, slowly progressive, nonhemorrhagic, fibrous en-
largement of maxillary and mandibular keratinized gin-
giva (MIM 135300). Keratinized oral gingiva constitutes
a developmentally unique and functionally important
component of the masticatory mucosa surrounding the
teeth. Insufficient gingiva can predispose to chronic in-
fection, pathologic recession, and oral morbidity (Smith
1997). Chronic infection of the gingival-tooth interface
can result in periodontitis, an important oral pathology
having potential systemic consequences (Scannapieco
1998). Too much oral gingiva is associated with im-
proper tooth eruption resulting in malocclusion. The se-
verity of gingival overgrowth in HGF varies among af-
fected individuals and, in severe cases, can prevent tooth
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eruption, resulting in functional and aesthetic problems
(Raeste et al. 1978). Treatment by surgical resection is,
in some cases, followed by a regrowth of the gingival
tissues. HGF may be transmitted as a Mendelian trait,
and both autosomal dominant and autosomal recessive
transmission have been reported (Jorgenson and Cocker
1974). Linkage studies have localized loci for isolated,
nonsyndromic autosomal dominant forms of gingival
fibromatosis to chromosome 2p21-p22 (Hart et al.
1998; Xiao et al. 2000) and to chromosome 5q13-q22
(Xiao et al. 2001). In addition to nonsyndromic forms,
gingival fibromatosis has been associated with a variety
of syndromic manifestations. Chromosomal anomalies
reported for syndromic forms of gingival fibromatosis
include duplications, deletions, and/or other anomalies
of chromosomes 2p13-16 (Fryns 1996; Shashi et al.
1999), 4q (MIM 252500), 8 (MIM 266270), 14q (Ri-
vera et al. 1992), 19p (MIM 246200), 19q (MIM
248500), and Xq (Macias-Flores et al. 1984). Gingival
fibromatosis is also an unwanted side effect of several
pharmacological agents, including dilantin, cyclosporin,
and several calcium-channel blockers (reviewed in Has-
sell and Hefti 1991). This drug-induced overgrowth re-
sponse varies between individuals and may reflect an
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Figure 1 Pedigree of Brazilian family with hereditary gingival fibromatosis. Affected individuals are indicated by blackened symbols.
Circles denote females, and squares denote males; a slash through a symbol denotes a deceased individual. Clinically unaffected individuals are
indicated by an unblackened symbol. A clinical diagnosis of unknown (or an uncertain diagnosis) is denoted by a question mark (?) within the
symbol. The proband is indicated by the arrow (↗). The flattened oval symbol indicates individuals who participated in this study.
underlying, genetically determined susceptibility (Sey-
mour et al. 1996).
Two groups have previously linked autosomal dom-
inant HGF to an overlapping interval of chromosome
2p (Hart et al. 1998; Shashi et al. 1999; Xiao et al.
2000). As part of our ongoing efforts to identify the
genetic basis for gingival fibromatosis, we developed a
physical map spanning the HGF1 candidate interval,
permitting us to integrate and localize 32 genetic mark-
ers and 33 genes to the interval (M.C.G. and T.C.H.,
unpublished data). In the present study, we describe the
refinement of the HGF1 locus to a 2.3-Mb interval by
extension of the pedigree and genotyping additional
markers in the region. Sequence analysis of 6 known
candidate genes, as well as 10 additional, previously
uncharacterized genes within the refined interval, per-
mitted us to identify a mutation, in the Son of seven-
less–1 (SOS1) gene, that segregated with the HGF phe-
notype. In this report, we describe the genomic organ-
ization of the SOS1 gene and present evidence that a
single-nucleotide–insertion mutation in codon 1083 of
the SOS1 gene is the cause of HGF1 in humans.
Subjects and Methods
Pedigree and Diagnosis
A large, multigenerational Brazilian family segregat-
ing HGF as a highly penetrant autosomal dominant trait
was identified by proband ascertainment. Linkage stud-
ies of part of this family led to the original linkage of
HGF1 to chromosome 2p21 (Hart et al. 1998). Individ-
uals examined for the current study are shown in figure
1. All participating family members provided informed
consent to protocols approved by institutional review
boards at the University of Taubate and the University
of Pittsburgh. All individuals received oral and dental
exams and, on the basis of the presence or absence of
gingival enlargement, were classified as affected or un-
affected, as described elsewhere (Hart et al. 1998). All
individuals were also asked about exposure to prescrip-
tion and nonprescription medications and, specifically,
about exposure to medications associated with gingival
overgrowth, including phenytoin, cyclosporin, and cal-
cium-channel blockers.
DNA-Marker Analysis
Genomic DNA was extracted from peripheral blood
by standard methods using the QIAamp blood kit (Qia-
gen). Available family members were genotyped for
STRP-type genetic markers spanning the candidate in-
terval. In addition to 11 previously reported STRP loci,
21 novel STRP loci were developed from a 6-Mb phys-
ical map of the interval (M.C.G. and T.C.H., unpub-
lished data). These marker loci were PCR amplified by
use of fluorescence-labeled primers, permitting genotyp-
ing by conventional methods (Zhang et al. 2001). PCR
products were detected by an ABI377 fluorescent se-
quencer and were analyzed by GENESCAN2.1 (Applied
Biosystems). Alleles were determined, and genotype data
were entered into the pedigree file of the LINKAGE soft-
ware package (Lathrop and Lalouel 1984).
Parametric Linkage Calculations: LOD Scores
Sublocalization of the candidate interval for HGF1 on
chromosome 2p21-p22 was achieved by means of ge-
netic linkage studies. We calculated two-point LOD
scores in the extended kindred, using the Elston-Stewart
algorithm (Elston and Stewart 1971), employing the
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LINKAGE program (Lathrop and Lalouel 1984) with
updates to speed calculations (VITESSE and FASTLINK;
see Cottingham et al. 1993; Terwilliger and Ott 1994;
O’Connell and Weeks 1995). The LOD-score analyses
assumed a genetic model for HGF, with autosomal dom-
inant transmission, disease-allele frequency of 0.0001,
0%–1% phenocopy rates, and 95% penetrance.
Multipoint LOD-Score Calculations
TheMarkov chain–Monte Carlo (MCMC) algorithm,
as implemented in the computer program SimWalk2 (So-
bel and Lange 1996), was used for the multipoint LOD-
score calculations.
Analysis of Genes within the Candidate Interval,
Identification of the SOS1 Genomic Region, and SOS1
Exon Sequencing
Using bioinformatic approaches, we identified, assem-
bled, and aligned 64 BACs, to develop a 6-Mb integrated
physical and genetic map spanning the HGF1 candidate-
gene region on chromosome 2p21-p22 (Zhang et al., in
press; M.C.G. and T.C.H., unpublished data). By means
of linkage analyses, we refined the HGF1 candidate in-
terval to a 2.3-Mb interval. We localized six known
genes to this region. Additionally, using an integrated
bioinformatic and bench lab approach, we identified 10
previously uncharacterized genetic loci within the inter-
val. All exons and intron-exon boundaries of these 16
genes were analyzed by sequence analysis. For these
analyses, genomic DNA from three HGF1 affected in-
dividuals and from two unaffected (control) individuals
were sequenced. Details for sequencing of all genes, in-
cluding their GenBank accession numbers, will be re-
ported separately (Zhang et al., in press; M.C.G. and
T.C.H., unpublished data). The genomic structure of the
SOS1 gene was determined bioinformatically and was
confirmed by sequence analysis. To determine the ge-
nomic organization for the entire SOS1 gene, all avail-
able SOS1mRNA and EST data were aligned to identify
any possible splice variants. Exon 1 was identified from
the dbEST data (NCBI dBEST Web site), since all avail-
able mRNA information began at the ATG start site in
exon 2. Primers were designedwithOligo 4.02 (National
Biosciences) to amplify each exon, including exon-intron
boundaries for sequence analysis (table 1).
PCR amplification of the SOS1 gene was performed
as indicated in table 1, with or without Enhancer (Life
Technology). Amplified DNAwas purified with theQIA-
quick PCR Purification Kit (Qiagen) and was sequenced
using the BigDyeTerminator Cycle Sequencing Kit and
ABI 3700 or 310 DNA analyzer (Applied Biosystems).
Sequencing was performed by use of the amplification
primers and appropriate sequencing primers, as indi-
cated in table 1. Sequence analysis was performed with
Sequencher 4.1 software (GeneCodes). Genomic DNA
from three affected and two unaffected family members
was evaluated for the initial sequencing. Any polymor-
phism detected was evaluated for possible linkage to
HGF1 in a larger segment of the family.
RNA Verification of Wild-Type and Mutant SOS1
Peripheral venous blood was obtained by standard
venipuncture from affected individuals, and white blood
cells were isolated by Ficoll gradient separation, accord-
ing to the manufacturer’s instructions (Pharmacia). Gin-
gival tissues were collected from two affected individuals
946 Am. J. Hum. Genet. 70:943–954, 2002
Table 1










01–02 CTTGCGTTTCGGAGTCCCAACTAC AAGGGCAAAGCATTCACCTCTCAG 806 C AF441466
03 GGGTTGAGAACTCCTGACTTCTAG TTTCCCTGTTCACTGACATTACAA 659 B AF441467
04 TGTGATATTCCCCCTAGATAATAG CCCTTCTCACCACATAAATCTCTG 515 B AF441468
05 CATTTGCTCCCTTCCCCAAACTTG GATCTTCCCCAACACATAATACAA 464 A AF441469
06 CCAAGTCAGGGAAATTAAAGACAG TGGAGTACATGGAGAATTCTGTGA 761 A AF441470
07 AATACAGCCTCACTGAATTAATGT CCTTGGCGGTATCTGTCTTTCTAT 409 A AF441471
08-09 TAGTCGTGCCCCATAATTAAATCT TGTGCAGGGTACTCACACAATAAT 462 A AF441472
10 ATTACTGCCTGTCACAAGATATAA TCTAAAAGACCAGGCTTGTCACTA 501 A AF441473
11 AGTAGCCAAGATAGAAATAATCAT TCAAGCATCCTTTCCAGTGTACTC 1,230 A AF441474
11S AGGAGCCAAACATGAGAGACACAT AGATCCCAATAATGATGATTTACT
12 GTGTGCAGAGGGCAAGAAATAAGT AGGGTAATTCCAGAAAAACTGACT 731 A AF441475
13-14 AGTCCCGTAACTTTATAGTCACAT TTACTGAGCCCCAATGACATCAAT 911 A AF441476
13-14S GCGGTAAGCATTAAATAAATGAAG ACCGCAGTTGCACAGGCTGTATAT
15 GAACAATGGGATGGACAGTCTCTA TGCCTGGCCTTATTACTAGACACT 656 A AF441477
16 TAAGGAAATATGCATAATTACACT CTGCACTCCAGCCTATGTGACAGA 418 A AF441478
17 CTATCAGTCACCCTGAATGTGTCT GCTTAGGCTGGGACCTGTGAATAC 524 A AF441479
18 GTTGTATTTGGGCGTTTCTGTTAG AAGGCACAGCAGGCACACTATGAT 586 A AF441480
19–20 GTGACGAAGTTATTCTTAAAGTTC TTTGGCTGGGCACTGACAAGTAAC 1,400 A AF441481
19–20S GCAACTGAGATGGTACAGTGTAAT CATCTTTGATATCAGGATTTACTC
19–20S ATCAGCCTTACTGTTTACGAGTAG
21 AGGGCTTTAGCAAAATAGAATGTT ACTTGCAGATTTTAAGACTGATCT 776 A AF441482
22 TGCTTGAATTGGGTTTCTACAT AATGCTGCCAGACCCAAGAAGAGT 445 A AF441483
23 CACTGTCTCCCAGACATCTGAGAA TTAGGTTTACAAGGGTCTTGAATG 654 A AF441484
24 CCAGGAAGTTGAGGCTACAGTGAG TCGGTCTTTCCATATTCTAAACTG 944 D AF441485
24S CGGCCCAGCAATGGAATGAAGGTC
a S denotes primers used in sequencing reactions.
b The standard PCR amplification for each exon contains: Taq (0.025 U/ml), 1# PCR buffer, 25 nM each dNTP, and
Mg as follows: A p 4.0 mM Mg, 95-2′  94-30′′/55-30′′/72-2′ 35X  72C-10′, no enhancer. Bp 3.0 mM Mg, 95-2′ 
94-30′′/55-30′′/72-2′ 35X  72C-10′, no enhancer. C p 1.5 mM Mg, 95-2′  94-30′′/55-30′′/72-2′ 35X  72C-10′, 20%
enhancer. D p 1.5 mM Mg, 95-2′  94-30′′/55-30′′/72-2′ 35X  72C-10′, 5% enhancer.
during routine surgery for removal of the overgrown
gingival tissue. Total RNA was purified from both white
blood cells and homogenized gingival tissues by use of
Trizol solution (Life Technology). Approximately 1 mg
of total RNA from each tissue was reverse transcribed
using the Reverse Transcription System (Promega), with
both oligo dT and random primers. The cDNA products
were used as templates for a partial amplification of
SOS1mRNA exon 21–24 (808 bp) and exon 19-22 (501
bp) with primer sets U3174/L3958 (5′-GGAGCCAAGG-
AAAATTAGTTATAG-3′/5′-CCAACAGTGGTGGTC-
CATCTCTGT-3′) and U2831/L3310 (5′-ACCCTGAG-
GTCCTAAAAAGACATG-3′/5′-GCTCGAATGATCG-
GAATCAAATAC-3′), respectively. The PCR amplifica-
tion was performed with Taq DNA polymerase, at an
annealing temperature of 60C. The amplified products
were purified and sequenced as described above. The
DNA sequences were aligned with the human SOS1
cDNA in GenBank (accession number 306777). To
further confirm the mutant allele of the SOS1 cDNA,
the amplified PCR products were subsequently cloned
directly into the pGEM-Teasy vector (Promega), and
their sequences were confirmed by automated DNA
sequencing.
Screening for the SOS1 Exon 21 Insertion Mutation
Exon 21 of the SOS1 gene was sequenced in 78 avail-
able family members. To determine if the C insertion in
codon 1083 represented a SOS1 polymorphism present
in the general population, 208 chromosomes from clin-
ically unaffected white and Chinese controls (104 chro-
mosomes from each population) were also analyzed.
Western Blot Analysis
Total protein was extracted from gingival tissue by
homogenization in lysis buffer (1% SDS, 1.0 mM so-
dium ortho-vanadate, 10 mM Tris, pH 7.4). Cellular
lysates were electrophoresed on 6%SDS-polyacrylamide
gels. Following electrophoresis, separated proteins were
electroblotted onto polyvinylidine difluoride membrane.
The membrane was blocked in blocking buffer (5% dry
milk in phosphate-buffered saline) for 1 h at room tem-
perature and then was incubated with 1 mg/ml primary
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Figure 2 An indication of the relative positioning of STRPmark-
ers used in our analysis and genes with known functions identified in
the region. All genes from CEP3 to SLC8A1 were sequenced in our
search. CRIM1p cysteine-rich motor neuron 1 (locus 51232); FEZ2
p fasciculation and elongation protein zeta 2 (locus 9637); STRNp
striatin (locus 6801); PRKR p protein kinase, interferon-inducible
double-stranded RNA dependent (locus 5610); CBF2-CCAATp box
binding transcription factor (locus 10153); PRKCNp protein kinase
C, nu (locus 23683); QPCT p glutaminyl-peptide cyclotransferase
(locus 25797); CEP3 p cdc42 effector protein 3 (locus 10602);
CYP1B1p cytochrome P450, subfamily 1, polypeptide 1 (locus1545);
ARL6ip2p ADP-ribosylation-like factor 6 interacting protein 2 (locus
64225); RPLPOp ribosomal protein, acidic, P0 (locus 6175); SFRS7
p splicing factor, arginine/serine-rich 7 (locus 6432); SOS1p son of
sevenless (D. melanogaster) homolog 1(locus 6654); MAP4K3p mi-
togen-activated protein kinase kinase kinase kinase 3 (locus 8491);
and SLC8A1 p solute carrier family 8 (sodium/calcium exchanger),
member 1 (locus 6546). All loci can be accessed through LocusLink.
The total region covered corresponds to 5,500,000 bases.
antibody in blocking buffer for 3 h. After rinsing, the
membrane was incubated with peroxidase-conjugated
secondary antibody for 1 h followed by chemilumines-
cence detection (NEN). Primary antibodies were rabbit
anti-mouse Sos1, a polyclonal generated by immuniza-
tion with a synthetic peptide corresponding to amino
acids 1241–1260 in the C-terminus of the mouse Sos1
and the monoclonal anti-mouse Sos1, directed against
the N-terminus of mouse Sos1 (BD Biosciences). The
primary antibodies are known to cross-react with human
SOS1 (170 kDa). The N-terminal antibody also cross-
reacts with human SOS2 (150 kDa). The secondary an-
tibodies were goat anti-rabbit and goat anti-mouse for
the polyclonal and monoclonal primaries, respectively.
Results
Clinical Findings
An extended, multigenerational kindred segregating
HGF was studied. Ninety-two family members were
clinically examined, and blood was available from 82
family members for DNA analysis. Photographs, med-
ical records, and family histories permitted a diagnosis
in 14 deceased individuals. Thirty-eight individuals were
diagnosed as affected, and 40 family members were di-
agnosed as unaffected (fig. 1). A diagnosis could not be
determined in five individuals. Two individuals, V-2 and
V-34, reported a history of taking dilantin. Because of
the association with gingival overgrowth in 15%–30%
of individuals taking dilantin, both individuals were
given a diagnosis of unknown. A diagnosis could not be
determined in three additional individuals: two were
children under the age of 6 years (VI-2 and VI-4), and
one was an edentulous adult (III-23). No family mem-
bers reported a history of hearing loss or epilepsy, and
hypertrichosis was not observed in any individuals. All
family members were otherwise healthy and of normal
intelligence. HGF was present in all generations, male-
to-male transmission was observed, and there were ap-
proximately equal proportions of affected males and fe-
males, findings consistent with autosomal dominant
transmission of the HGF phenotype. Clinical findings
are consistent with a diagnosis of isolated, nonsyn-
dromic hereditary gingival fibromatosis.
Development of a Physical Map of the HGF1
Candidate Interval
A 6-Mb integrated physical and genetic map spanning
the HGF1 candidate interval was developed (M.C.G.
and T.C.H., unpublished data). This map permitted
identification and localization of 32 STRP-type genetic
markers and 33 genes to the interval. The integration of
polymorphic genetic markers and genes in the interval
permitted us to systematically refine the region segre-
gating with the HGF1 phenotype. A schematic of the
region containing the smallest genetic interval segregat-
ing with the HGF1 phenotype in the Brazilian kindred
studied is shown in figure 2. The refined interval is 2.3
Mb, flanked by the STRP markers 92F3-01 and
D2S2238. Also indicated in figure 2 is the centromeric
portion of the HGF candidate interval reported by Xiao
et al. (2000), which extends in a telomeric direction from
D2S2163. This refined candidate interval contained 6
known genes and 10 novel genes (table 2).
Linkage Analyses
Results of linkage analysis for 26 STRP markers span-
ning the candidate interval are given in table 3 (two-
point analyses) and figure 3 (multipoint analysis). On
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Table 2
Genes Identified within the Refined 2.3-Mb HGF1 Candidate Interval on 2p21-22







CEP3 Cdc42 effector protein 3 10602 NM_006449
BLOCK 18 Unknown AK057516 AF450120-AF450129
CYP1B1 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 1545 NM_000104 AF450130-AF450132
ARL6ip2 ADP-ribosylation-like factor 6 interacting protein 2 64225 NM_022374 AF449176-AF449187
BLOCK 22 Unknown AF447702-AF447707
BLOCK 23 97% homology to ribosomal phosphoprotein, acidic, P0 AY064377
BLOCK 24 Unknown, similar to human heterogeneous nuclear ribonuclear
protein L 92906 AK000155
BLOCK 25 Unknown, 88% homology with aldose-1-epimerase from Sus
scrofa BC014916 AY064378-AY064385
SFRS7 Splicing factor, arginine/serine-rich 7 6432 NM_006276 AY062913-AY062919
BLOCK 26 Unknown
BLOCK 27 Unknown AF449188-AF449191
BLOCK 28 Unknown AF454826-AF454826
SOS1 Son of sevenless (D. melanogaster) homolog 1 6654 NM_005633 AF441466-AF441485
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 8491 NM_003618 AF445385-AF445413
BLOCK 35 Unknown, SAM-dependent methyltransferase 80745 AF380566-AF380576
SLC8A1 Solute carrier family 8 (sodium/calcium exchanger), member 1 6546 NM_021097
NOTE.—Genes were identified as indicated in the “Subjects and Methods” section. No gene without an EST and/or cDNA sequence
was considered.
the basis of haplotype analysis, we were able to refine
the candidate interval to ∼2.3 Mb, within a genetic in-
terval flanked by the novel marker loci 92F3-01 and
D2S2238. The maximum two-point LOD score was for
the marker D2S2220, at recombinationZ p 14.26max
fraction (v) 0.00. The marker locus 173C1-01 is located
within intron 7 of the SOS1 gene at(Z p 12.08max
). The maximum multipoint location score wasvp 0.00
for D2S2220. Using the criteria of ZMAXZ p 20.18max
–1.0 LOD, to determine the 95% CI, we placed the
HGF1 locus within an ∼1.6-Mb interval flanked by
92F3-01 and 288L6-01 (Conneally et al. 1985).
Genomic Structure of the SOS1 Gene
The alignment of available ESTs (batch download
from Unigene Hs.326392) and mRNA for SOS1 with
genomic sequences from two BACs (RP11-173C1 and
R911-603F24) permitted identification and localization
of 24 exons of the SOS1 gene. One splice variant in-
volving exon 22 was identified (Rojas et al. 1996). The
genomic organization of the SOS1 gene is shown in fig-
ure 4. The SOS1 gene spans 136 kb and consists of 24
exons. The intronic sizes range from 30 bp to 53 kb.
The open reading frame contains 4,002 nucleotides and
encodes 1,333 amino acids (hSOS1 mRNA; GenBank
accession number 306777). The translation initiation co-
don is located at nucleotides 45–47 of exon 2, whereas
the open reading frame is terminated at nucleotide 492
in exon 24.
Mutational Analysis
A total of 16 genes were sequenced from the 2.3-Mb
candidate interval. A number of exonic and intronic
polymorphisms were identified but were found not to
segregate with the HGF phenotype (data not shown). A
complete list of these genes is presented in table 2. Direct
DNA sequencing of the SOS1 gene identified 12 intronic
SNPs spanning the SOS1 gene (data not shown). None
of these SNPs appeared to affect splice-site junctions,
and none segregated with the HGF disease phenotype
in this extended kindred. One exonic sequence alteration
differed from the wild-type SOS1 mRNA structure re-
ported elsewhere. This single-nucleotide (cytosine) in-
sertion (c.3248-3249insC) in exon 21 was identified in
all individuals affected with HGF1 (fig. 5). This alter-
ation segregated with the HGF phenotype and was not
identified in any unaffected family members nor in any
of the control chromosomes tested (104 from white sub-
jects and 104 from Chinese subjects). The insertion of
a single C nucleotide into codon 1083 does not change
the coded amino acid (proline), but it does introduce a
frameshift at codon 1084 of the SOS1 gene. This frame-
shift mutation is predicted to alter the subsequent 22
amino acids (1084–1105) and to introduce a premature
stop codon at codon 1106 (fig. 5). The predicted protein
chimera does not contain the proline-rich Grb2 binding
domains nor the five MAP kinase phosphorylation sites
that are normally present in the wild-type SOS1 protein.
The presence of both the normal and mutant SOS1 tran-
scripts was demonstrated in RT-PCR from mRNA iso-
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LOD SCORE AT v p
.0 .01 .05 .10 .20 .30 .40
D2S2230 0 1.82 5.87 6.12 5.76 4.54 3.09 1.56
501007 140 3.19 3.14 2.92 2.64 2.02 1.35 .64
D2S2186 430 .07 3.23 3.78 3.75 3.14 2.20 1.10
531C11-02 680 6.51 9.40 8.87 8.08 6.28 4.27 2.10
423P10-02 780 10.00 9.93 9.50 8.78 7.00 4.90 2.55
429J10-01 1,050 1.28 5.76 5.96 5.60 4.42 2.99 1.47
278G12-03 1,130 7.85 8.11 8.06 7.47 5.78 3.71 1.52
278G12-02 1,140 2.23 2.20 2.08 1.89 1.40 .85 .34
D2S2163 1,220 .67 6.53 7.30 6.99 5.54 3.64 1.60
D2S177 1,330 11.29 12.97 12.70 11.70 9.18 6.27 3.07
92F3-01 1,400 6.78 3.12 .53 .39 .94 .88 .54
92F3-02 1,520 7.54 7.42 6.94 6.30 4.86 3.24 1.44
081H20-01 1,565 7.63 7.50 6.95 6.26 4.80 3.19 1.43
D2S1346 1,570 14.25 14.00 12.96 11.62 8.82 5.83 2.72
GATA190D04 1,730 6.93 6.81 6.30 5.63 4.22 2.72 1.20
D2S2220 1,800 14.26 14.02 13.04 11.75 9.01 6.05 2.92
173C1-01 2,570 12.08 11.91 11.19 10.21 8.03 5.61 2.92
288L6-01 3,210 7.27 7.18 6.78 6.21 4.90 3.40 1.75
D2S2238 3,470 11.33 11.66 11.54 10.73 8.40 5.51 2.32
509C20-01 3,580 6.96 7.06 7.10 6.81 5.67 4.08 2.13
3F16-01 3,710 5.32 10.61 10.55 9.82 7.79 5.37 2.65
D2S2272 4,190 .16 7.85 7.83 7.21 5.54 3.60 1.56
D2S2172 5,270 .09 7.37 7.40 6.82 5.25 3.43 1.55
D2S1356 5,670 6.47 10.15 10.56 10.02 8.07 5.56 2.71
D2S2259 6,570 2.36 6.71 7.45 7.27 6.05 4.29 2.19
D2S119 7,170 9.43 9.61 9.57 9.02 7.31 5.17 2.67
a Marker distances relative to D2S2230, as reported from an integrated physical and
genetic map of the candidate interval (M.C.G. and T.C.H., unpublished data). D2S2230 is
56.15 cM from the 2p telomere (Marshfield genetic map; Broman et al. 1998).
lated from both white blood cells and from gingival tis-
sue of affected individuals, verifying that the mutant
SOS1 allele is transcribed.
Western Blot Analysis
Western blot analysis with a mouse monoclonal an-
tibody directed against the N-terminus of the SOS1 pro-
tein revealed the expected ∼170 kDa wild-type band in
all samples, as well as an ∼150-kDa band that is con-
sistent with a cross-reactive band for the smaller-sized
Son of sevenless–2 protein (SOS2) (data not shown). An
additional, smaller band of ∼143 kDa, consistent with
the truncated SOS1 protein, was present in western blots
for HGF gingival-tissue extracts. Western blot analysis
with a polyclonal antibody directed against amino acids
1241–1260 of the mouse Sos1 protein revealed a pre-
dominant band of 170 kDa in all samples tested, cor-
responding to the wild-type protein. In addition to the
wild-type protein, we consistently observed a doublet
band at a high molecular weight (1200 kDa) in gingival
tissue from an affected individual. The stoichiometry of
the two bands in the doublet differed for the two dif-
ferent antibodies. When the C-terminal SOS1-specific
antibody was used, both bands in the doublet were of
equal intensity. The intensity of the lower–molecular-
weight band in the doublet was significantly enhanced,
with a ratio of ∼1:2 (upper:lower bands) when the N-
terminus–specific antibody was used. These findings are
consistent with the upper–molecular-weight band con-
taining the wild-type SOS1 protein and the lower–
molecular-weight band containing both the wild-type
and the mutant SOS1 protein.
Discussion
The findings of this study indicate that alteration of the
carboxyl-terminal domain of the SOS1 protein is respon-
sible for HGF1 in an extended kindred. Genetic linkage
studies localized a gene for HGF1 to a genetic interval
containing the SOS1 gene locus. Sequence analysis of ge-
nomic DNA and mRNA from individuals affected with
HGF1 identified a single-cytosine insertion in exon 21 of
the SOS1 gene. On the basis of nomenclature guidelines
(Antonarakis 1988), we have designated the insertion be-
tween nucleotides 126,142 and 126,143 in the genomic
sequence (g.126,142-126,143insC) and between nucle-
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Figure 3 Multipoint LOD analysis of the family in the 7.5-cM interval flanking the refined HGF1 candidate interval. LOD scores are
given on the X-axis, and genetic distances are indicated on the Y-axis from the telomeric end of chromosome 2p, on the left. The position of
each of the 26 STRP markers tested are indicated by Roman numerals in the figure. The name corresponding to each number is indicated in
the key below the figure.
otides 3248 and 3249 in the SOS1 cDNA sequence
(c.3248-3249insC). The codon for amino acid 1083 is
changed from CCA to CCC. Both CCA and CCC code
for proline, but the additional nucleotide produces a
frameshift and an early termination of the protein (fig.
5). This mutation yields a chimeric 1,105–amino acid
protein that consists of 1,083 SOS1 N-terminal amino
acids followed by 22 replaced amino acids and a pre-
mature stop codon at codon 1106 (p.K1084fsX1105).
We believe that this mutation is the cause of HGF1 on
the basis of several findings. First, there is complete cos-
egregation between the g.126,142-126,143insC insertion
and the HGF phenotype in this kindred. This nucleotide
change is not present in 208 control chromosomes from
unrelated healthy individuals. Second, SOS1 is expressed
in gingival tissues, the site that is clinically affected in
HGF. Both the wild-type and mutant transcripts are ex-
pressed in gingival tissues of affected individuals.Western
blot experiments are consistent with expression of both
wild type and mutant SOS1 protein in gingival tissue
from individuals affected with HGF1. Third, the highly
conserved 1,333–amino acidwild-type human SOS1pro-
tein is constitutively maintained in a down-regulated
state. The carboxyl-terminal domain exerts negative al-
losteric control on the interaction of the SOS1 catalytic
domain with Ras (Corbalan-Garcia et al. 1998). The
p.K1084fsX1105 mutation deletes ∼20% of the SOS1
protein, including functional domains that maintain
SOS1 in a down-regulated state. The truncated SOS1
protein is therefore predicted to have enhanced activity.
Studies in several species—including yeast, Drosophila
melanogaster, mouse, and human—indicate that trun-
cation of the carboxyl-terminal portion of SOS1 is as-
sociated with a gain of function. Finally, a transgene con-
struct with an SOS1 carboxyl-terminal deletion induces
skin-tumor development in mice. On the basis of these
findings, we hypothesize that the g.126,142-126,143insC
mutation produces the truncated protein chimera
p.K1084fsX1105 that causes HGF1 through a gain-of-
function mechanism.
The guanine nucleotide-exchange factor SOS1 me-
diates the coupling of receptor tyrosine kinases to Ras
activation (Corbalan-Garcia et al. 1996). The SOS1
protein has been studied extensively and the functional
domains and crystal structure of the SOS1 protein are
known (Soisson et al. 1998; Chen et al. 1999; Wasiak
et al. 2001). The human SOS1 protein contains six well-
characterized functional domains, two of which are en-
coded by nucleotides 3′ to codon 1083 (fig. 4). These
include four proline-rich SH3-binding sites and five mi-
togen-activated protein (MAP) kinase phosphorylation
sites. Although the wild-type SOS1 protein is consti-
tutively maintained in a down-regulated state, human
SOS1 truncation mutants that lack either the amino
terminus or the carboxyl-terminal domain display gua-
nine nucleotide-exchange activity that is significantly
greater than that in the full-length protein (Corbalan-
Garcia et al. 1998).
Similar to the situation in humans (Aronheim et al.
1994), deletion of the proline-rich region in SOS1 is
also associated with enhanced SOS1 activity in D. me-
lanogaster (McCollam et al. 1995) and yeast. Addi-
tionally, a transgenic mouse model of a similar SOS1
mutation (called “SOS-F”) is associated with a domi-
nant skin phenotype (Sibilia et al. 2000). In the SOS-F
transgene construct, the C-terminal region containing
the Grb2 binding site has been deleted. When the SOS-
F construct is expressed in basal keratinocytes by use
of a keratin 5′ promoter, multiple papillomas and skin
hypertrophy were observed. The skin-tumor phenotype
is 100% penetrant in mice with the SOS-F mutation.
These data suggest that a C-terminal truncation of the
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Figure 4 Structure of the human SOS1 gene. A, Genomic organization of the SOS1 gene. The exons and introns are represented as
vertical and horizontal lines, respectively. The sizes of each intron are shown in kb. B, cDNA structure of the SOS1 gene. The location of each
exons are shown with the nucleotide numbers (bp). Since we did not determine the exact termini of the SOS1 cDNA, the N- and C-terminals
are marked with dashed lines. The translation start and stop codon are labeled as ATG and TGA, respectively. The asterisk (*) marks the single-
nucleotide (C) insertion between nucleotides 3248 and 3249. The 5′ and 3′ UTRs are shaded. C, Structure of the wild-type SOS1 protein. The
location of each domain is marked by the amino acid numbers, with the initiation Met as amino acid 1. RhoGEF p guanine nucleotide-
exchange factor for the Rho-Rac/cdc42-like GTPases region. PH p Pleckstrin homology domain. RasGEFN p guanine nucleotide-exchange
factor for Ras-like GTPases; N-terminal motif. RasGEF p guanine nucleotide-exchange factor for Ras-like GTPases. PRGB p proline-rich
Grbs-binding domain. In the PRGB domain, the location of the four proline-rich SH3 binding sites and the five phosphorylated serine residues
are indicated by P and S, respectively. Codon 1083 (proline), where the single-nucleotide insertion occurs in HGF1, is indicated as P1083. D,
Structure of the mutant SOS1 protein identified in patients with HGF. The 22–amino acid missense addition at the C-terminal end are marked
with a black-diamond pattern.
SOS1 protein is functional and could produce the gin-
gival overgrowth clinically observed in human HGF1
with the SOS1 mutation. Why the HGF phenotype ap-
pears localized to the gingiva is unknown. The keratin-
ized masticatory mucosa is recognized to be develop-
mentally unique (Gao and Mackenzie 1992), and
different tissue-specific signaling pathways in this
unique tissue may be responsible for the limited tissue
distribution of the gingival fibromatosis phenotype. Al-
though the site-specific localization of this phenotype is
remarkable, the gingiva is also the only site affected in
drug-induced and most syndromic forms of gingival
fibromatosis.
Interpretation of western blot analyses of extracts
from human gingiva with SOS1 antibodies are compli-
cated by the cross-reactivity of SOS1 antibodies with
the related SOS2 protein (∼150 kDa), and by the pres-
ence of SOS1 as part of high–molecular-weight com-
plexes (1200 kDa) in gingiva. Nonetheless, protein ex-
tracts from HGF-affected tissues were consistent with
the presence of a truncated SOS1 protein band (143
kDa). However, it appears that the majority of the trun-
cated (mutant) protein is associated in the high molec-
ular-weight complex, thus supporting a functional role
for the truncated protein. Although the components of
the high molecular-weight species are not known, SOS1
has been reported to form a complex with Grb2 (Li et
al. 1993), src-type tyrosine kinase (Park et al. 1998),
and phospholipase C-g1 (Kim et al. 2000). A complex
is also observed between Grb2/SOS1 and the epidermal
growth factor (EGF) receptor after EGF stimulation (Hu
and Bowtell 1996). The ability of mutant SOS1 protein
to form complexes may lead to constitutive activation
of its downstream targets.
The genetic basis for gingival fibromatosis in humans
is heterogeneous (Witkop 1971; Gorlin 1990; Hart et
al. 2000). Loci for autosomal dominant HGF have been
localized to an overlapping interval on chromosome
2p21-p22 (Hart et al. 1998; Shashi et al. 1999; Xiao et
al. 2000), suggesting that a gene locus within the 3.8-
cM overlap may be causal for HGF1. Evaluation of
linkage data presented here, by use of a recently devel-
oped 6-Mb integrated physical and genetic map of the
HGF1 candidate interval, indicates that the two chro-
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Figure 5 Mutation in SOS1, revealed by sequencing of exon 21. The ATG translation initiation codon, encoded by exon 2, is taken as
nucleotide 1. A, Sequences of (a) wild type, (b) genomic DNA from an affected individual, and (c) cloned affected cDNA allele amplification
from an affected individual. The insertion of a C nucleotide in genomic sequences between nucleotides 126,142 and 126,143 (b) and in cDNA
between nucleotides 3248 and 3249 (c) are shown by arrows. p.R1084fsX1105 indicates that this mutation produces a frameshift with
Arginine1084 as the first amino acid affected and that the new reading frame is open for 22 amino acids. B, Amino acid sequences of codons
1083–1106 of the wild type and predicted amino acid sequences of the mutant SOS1 proteins. The premature termination codon is indicated
by “Stop.”
mosome 2p21-p22 HGF linkage intervals are distinct
(fig. 2). The SOS1 gene locus is ∼1.3 Mb centromeric
to the linkage interval reported in Chinese families af-
fected with HGF (Xiao et al 2000). Whether there are
two distinct HGF loci in close proximity on chromo-
some 2p21-p22 is unknown. Mutational analysis of the
SOS1 gene in families demonstrating linkage to chro-
mosome 2p21-p22 may clarify genetic heterogeneity of
HGF.
The SOS1 mutation in individuals with HGF de-
scribed in this report represents the first genetic muta-
tion identified for isolated HGF. Whether the increase
in gingival tissue observed in the HGF1 phenotype is a
result of increased cellular proliferation, increased cell
survival, and/or inhibition of cellular differentiation is
not known. Identification of the specific genetic basis
in HGF1 should help to elucidate the pathogenic mech-
anism by which gingival overgrowth occurs. Under-
standing the mechanism by which gingival fibromatosis
develops may have implications for understanding how
certain drugs induce gingival overgrowth and may have
applications for the nonsurgical treatment of gingival
insufficiency.
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